A myeloperoxidase promoter polymorphism is independently associated with mortality in patients with impaired left ventricular function.

• Autoři: RUDOLPH V; RUDOLPH TK; KUBALA Lukáš; CLAUBERG N; MAAS R; PEKAROVÁ Michaela; KLINKE A; LAU D; SZÖCS Katalin; MEINERTZ T; BÖGER RH; BALDUS S
• Rok publikování: 2009
• Druh: Článek v odborném periodiku
• Časopis / Zdroj: FREE RADICAL BIOLOGY AND MEDICINE
• Fakulta / Pracoviště MU: Přírodovědecká fakulta
• www: http://www.ncbi.nlm.nih.gov/pubmed/19735726
• Doi: http://dx.doi.org/10.1016/j.freeradbiomed.2009.09.001
• Klíčová slova: Myeloperoxidase; Genetics; Heart failure; Survival; Free radicals
• Popis: Circulating levels of myeloperoxidase (MPO), a heme enzyme released upon activation of polymorphonuclear neutrophils, predict adverse outcome in patients with impaired left ventricular (LV) function.Interestingly, we observed no association of the MPO polymorphism with total MPO protein concentration or MPO activity in plasma. The 463 GA MPO polymorphism is linked to adverse clinical outcome of patients with impaired LV function. Further studies are needed to elucidate the value of this polymorphism for risk stratification.